Viridian Therapeutics, Inc. $VRDN Stock Position Decreased by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 25.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 309,133 shares of the company’s stock after selling 106,856 shares during the period. JPMorgan Chase & Co. owned about 0.32% of Viridian Therapeutics worth $6,671,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of VRDN. Commodore Capital LP raised its position in shares of Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after buying an additional 1,275,000 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Viridian Therapeutics by 314.9% in the third quarter. Wellington Management Group LLP now owns 1,122,532 shares of the company’s stock valued at $24,224,000 after acquiring an additional 851,989 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of Viridian Therapeutics by 135.6% during the third quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company’s stock valued at $25,922,000 after acquiring an additional 691,267 shares during the period. Rice Hall James & Associates LLC raised its holdings in Viridian Therapeutics by 65.2% during the third quarter. Rice Hall James & Associates LLC now owns 851,663 shares of the company’s stock worth $18,379,000 after purchasing an additional 336,040 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Viridian Therapeutics by 33.8% during the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after purchasing an additional 310,998 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on VRDN. The Goldman Sachs Group decreased their price target on Viridian Therapeutics from $41.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday. Evercore reissued an “outperform” rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 20th. Wedbush cut their price objective on Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating for the company in a report on Tuesday. William Blair assumed coverage on Viridian Therapeutics in a research note on Wednesday, December 3rd. They set an “outperform” rating for the company. Finally, Wells Fargo & Company lowered their target price on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a report on Tuesday. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.21.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL?1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell?side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a “buy” rating, Wedbush cut to $37 and kept “outperform”, and Needham trimmed to $32 while retaining “buy” — these keep a material upside narrative for investors who focus on longer?term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to “equal weight”, HC Wainwright cut to $22 (still “buy”) — these downward revisions compress near?term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit?taking; coverage highlighting the selloff and “stock tumbles despite trial success” may amplify short?term selling pressure. Investing.com

Viridian Therapeutics Trading Up 5.6%

Shares of NASDAQ VRDN opened at $19.56 on Wednesday. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $34.29. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -5.95 and a beta of 1.00. The business has a fifty day simple moving average of $29.16 and a 200-day simple moving average of $27.89.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. Sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.